Dr. Daniel M. Skovronsky
Chief Science Officer & Pres., Lilly Research Laboratories
Skovronsky joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals Inc., where he had been CEO since founding the company in 2004. He has held various roles at Lilly, including VP of tailored therapeutics, VP of diabetes research, and most recently, SVP of clinical and product development.
- 2020 Fourth Quarter
Added to: Myriad Genetics Inc. - Salt Lake City, UT
Myriad Genetics is a molecular diagnostic company. Revenues are $639 million.